Business
In Preparation for FDA Clearance and Device Deployment, Inspira has Appointed Dr. Dan Gorfil, to Medical Advisory Board
RA'ANANA, Israel, Dec. 11, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a pioneer in
About this update from Qtrex Quantum Ltd.
[{"type":"text","content":"RA'ANANA, Israel, Dec. 11, 2023 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the \"Company\" or \"Inspira\"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, is pleased to announce the appointment of Dr. Dan Gorfil to its medical advisory board.\n\nDr. Gorfil is a distinguished specialist in cardiac surgery and intensive care medicine. Dr. Gorfil is both the head of the Cardiothoracic Surgery Intensive Care Unit and the Extracorporeal Membrane Oxygenation program at the Department of Cardiothoracic Surgery at Rabin Medical Center, Israel. Dr. Gorfil's expertise are expected to significantly contribute to the deployment of the INSPIRA™ ART100. U.S. Food and Drug Administration (FDA) approval is expected in the first half of 2024.\n\"My commitment to life support innovation led me to Inspira Technologies,\" stated Dr. Gorfil. \"I believe that the Company's innovative technology will revolutionize critical care treatment. I am thrilled to be a part of this transformative journey.\"\nDagi Ben-Noon, CEO of Inspira Technologies, commented, \"Dr. Gorfil's appointment represents a strategic step towards accelerating our technology's time-to-market. I believe that his deep expertise and extensive network within the life support sector are valuable to both patients and our investors.\nInspira Technologies OXY B.H.N. Ltd.\nInspira Technologies is leading the way in transforming life-support care. Its innovative solutions are paving the way for direct blood oxygenation, bypassing the lungs, and potentially reducing the need for traditional mechanical ventilation. Beyond this, the Company is committed to advancing blood circulation technology and incorporating AI-driven monitoring systems. These advancements are part of its strategy to offer more patient-focused, data-informed care. The integration of these technologies signifies the potential to enhance patient outcomes and streamline hospital operations, marking a new era in respiratory care.\nFor more information, please visit our corporate website:\nhttps://inspira-technologies.com/\nForward-Looking Statement Disclaimer\nThis press release contains express or implied forward-looking statements under U.S. Federal securities laws. These forward-looking statements and their implications are based onl...